ArticleBasic and clinical neuroscience2025
Impact of Genotropin on Oxidative Stress, Glutamate, and Nitric Oxide Pathways in a Rat Model of Peripheral Neuropathy.
Article in Basic and clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Genotropin, a recombinant human growth hormone (GH), has been proposed as a potential repositioning drug to treat neurological disorders. However, its efficacy in managing neuropathic pain remains unclear. This study aimed to evaluate the analgesic effects of Genotropin and investigate its potential mechanisms of action. Methods: Two weeks after chronic constriction injury (CCI) of the sciatic nerve, adult male rats were randomly assigned to three main groups: Control, vehicle (normal saline [NS]), and treatment. The treatment group received Genotropin at doses of 0.3 and 0.6 mg/kg, either alone or in combination with L-arginine, L-NAME, or glutamate (n=8 per group). Pain-related behaviors were assessed using Von Frey filaments, the plantar test, and the Randall-Selitto test. Blood samples were collected to analyze oxidative and antioxidative markers. Results: Genotropin significantly reduced mechanical allodynia (P<0.05, F=2.7) and mechanical (P<0.01, F=3.4) and thermal hyperalgesia (P<0.001, F=2.5). Pretreatment with 0.3 mg/kg GH abolished the pronociceptive effects of L-arginine (500 mg/kg) and glutamate (1000 nmol) (P<0.01; F=2, F=3) while enhancing the antinociceptive effect of L-NAME (P<0.05, F=2.8). GH also significantly reduced lipid peroxidation (P<0.01, F=3.7) and restored levels of glutathione, glutathione peroxidase (GPx), and superoxide dismutase (SOD) (P<0.01; F=11, F=10.52, F=5, respectively). Additionally, catalase (CAT) levels were significantly increased (P<0.01, F=5). Conclusion: These results suggest that exogenous GH alleviates neuropathic pain and enhances antioxidant defenses in a model of peripheral neuropathic pain. The involvement of glutamate and nitric oxide (NO) pathways in GH's antinociceptive effects was also demonstrated. Therefore, Genotropin holds potential as a repositioned therapeutic agent for treating neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.